Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches

Not Applicable

Recruiting

• Conditions: Acute Myeloid Leukemia
• Interventions: Other: Adrenomedullin

• Registration Number: NCT04460963
• Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Brief Summary

The present study will be divided into 5 phases:

1. Collection of bone marrow and peripheral blood (PB) samples from AML patients at diagnosis;

2. Measurement of Midregional Proadrenomedullin (MR-proADM) plasma concentrations with an Immunoluminometric Assay of newly diagnosed AML patients not affected by concomitant cardiovascular disease or sepsis.

3. Analysis of exosomes and microvesicles derived from PB and bone marrow samples of AML patients and culture media collected from AML samples stimulated with ADM and/or ADM (22-52)

4. Study of adrenomedullin system in leukemic stem cells (CD44+/CD38-/CD31+/Lin-) in order to define a correlated expression of ADM and ADM receptors (RAMPs, PAM) with adhesion molecules (CD31, CD38, CD44s, CD44v6), cell cycle regulatory proteins (p21, p27) and genes or molecules involved in the hematopoietic differentiation process (Cul5, CD11b, CD11c, CD66, CD14, CD15, PML-RARα)

5. In vitro evaluation of ADM activity in the growth, maturation and trans-endothelial migration of blasts and/or fusion of leukemic cells with endothelial cells. To do this, leukemic cells will be alternatively cultured by using in vitro models of endosteal and vascular niches.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-06-25
• Study First Submitted QC: 2020-07-01
• Study First Posted: 2020-07-08
• Study Start: 2021-06-09
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-24
• Last Update Posted: 2022-11-28
• Primary Completion: 2024-06
• Study Completion: 2024-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

1. Patients with new diagnosis of primary or secondary AML.
2. Participant is willing and able to give signed written informed consent according to ICH/EU/GCP and national local laws.
3. Male or Female, aged >18 years.

Exclusion Criteria

1. Patients affected by concomitant cardiovascular disease , such as essential hypertension (any grade), chronic renal failure (creatinine>1.5 mg/dL), heart failure (any NYHA class), and peripheral arterial occlusive diseases, or sepsis.
2. Patients affected by HIV, B or C hepatitis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Biological evaluation	Adrenomedullin	Adrenomedullin evaluation at diagnosis at first CR and 1 year of follow-up

Primary Outcome Measures

Name	Time	Method
Evaluation of therapeutic potential of ADM inhibition on leukaemia stem cells	at 1 year	Rate estimation of the in vitro arrest of leukemic blasts proliferation by ADM inhibition.

Trial Locations

Locations (5)

Policlinico S. Orsola-Malpighi - Uoc Ematologia; 🇮🇹 Bologna, Italy

U.O. Oncoematologia IOV; 🇮🇹 Castelfranco Veneto, Italy

As Dell'Alto Adige, Ospedale Centrale Di Bolzano - Ematologia E Centro Trapianto Midollo Osseo; 🇮🇹 Bolzano, Italy

Ente Ecclesiastico Casa Sollievo Della Sofferenza - Ematologia; 🇮🇹 San Giovanni Rotondo, Italy

Uo Ematologia - Azienda Ulss N.2 Marca Trevigiana; 🇮🇹 Treviso, Italy